This novel anti-diabetic drug is a synthetic peptide analog of the human GIP hormone with a C20 fatty-diacid portion attached which, via acylation technology, can bind to albumin in order to provide a dose of the drug, by means of subcutaneous injection, once a week, which is appropriate to its a half-life of about five days
Pescado El pescado tambin contiene L-carnitina, especialmente el pescado azul como el salmn, la caballa y las sardinas

Mechanisms of Action Retatrutide activates three key receptors to modulate energy balance, appetite, and metabolism, leading to profound weight loss and glycemic control.[1][2] This triple agonism differentiates it from dual agonists like tirzepatide, enhancing fat oxidation and insulin sensitivity.[3][10] Key sub-mechanisms include: GLP-1 Receptor Activation : Suppresses appetite, delays gastric emptying, and promotes insulin secretion in a glucose-dependent manner.[1][11] GIP Receptor Activation : Enhances insulinotropic effects and improves beta-cell function, contributing to postprandial glucose control.[2][12] Glucagon Receptor Activation : Increases energy expenditure, promotes lipolysis, and supports hepatic fat reduction without significant hyperglycemia.[1][13] Synergistic Metabolic Regulation : Combines receptor effects to amplify weight loss through reduced caloric intake and increased thermogenesis.[3][14] Cardiometabolic Protection : Improves lipid profiles and reduces inflammation via multi-pathway modulation.[4][15] These mechanisms highlight Retatrutide's potential for compounding in therapies targeting obesity and related comorbidities

Leave-one-out sensitivity analyses confirmed the direction and magnitude of the AUD finding but highlighted the limited evidence base for hospitalization
This article will review the occurrence of GI AEs across different GLP-1 RAs and will outline current methods for their management
Do GLP-1 before and after results differ between men and women